Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics vs IVIG in IgG Subclass Deficiency
NCT00522821Phase 4Completed
- Sponsor
- Prothya Biosolutions
- Start
- Nov 2007
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Nanogam in IgG subclass deficiency (IgGSD), selective anti-polysaccharide antibody deficiency (SPAD), sponsored by Prothya Biosolutions. Started Nov 2007; status: completed.
02
Drugs
Nanogam
03
Conditions
IgG subclass deficiency (IgGSD)selective anti-polysaccharide antibody deficiency (SPAD)
Beyond the preview
Go deeper on NCT00522821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522821.